Joint Statement on "Three Priorities for Promptly Increasing Access to COVID-19 Vaccine
February 28, 2022
Japan Pharmaceutical Manufacturers Association
The Japan Pharmaceutical Manufacturers Association (JPMA; Chairman: Yasushi Okada) is pleased to announce the release of a statement on the "Three Priorities for Promptly Increasing Access to COVID-19 Vaccine" developed by national pharmaceutical associations.
The original text of this joint statement can be found here.
Three priorities to urgently increase access to COVID-19 vaccines
Please refer to the attached document* for a Japanese translation of the joint statement.
The attached document is a translation of a press release issued on February 25, 2022, by the pharmaceutical associations of each country and is provided for your reference. The official language is English, and English takes precedence in content and interpretation.
JPMA is committed to working with various stakeholders to help achieve improvements in vaccine equity.